ABBOTT LABORATORIES
For the period ended Dec 31, 2023. Filed Feb 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 16, 2024
ABT$109.93-3.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Earnings
(in millions except per share data)
| Year Ended December 31 | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net Sales | $40,109 | $43,653 | $43,075 |
| Cost of products sold, excluding amortization of intangible assets | 17,975 | 19,142 | 18,537 |
| Amortization of intangible assets | 1,966 | 2,013 | 2,047 |
| Research and development | 2,741 | 2,888 | 2,742 |
| Selling, general and administrative | 10,949 | 11,248 | 11,324 |
| Total Operating Cost and Expenses | 33,631 | 35,291 | 34,650 |
| Operating Earnings | 6,478 | 8,362 | 8,425 |
| Interest expense | 637 | 558 | 533 |
| Interest income | (385) | (183) | (43) |
| Net foreign exchange (gain) loss | 41 | 2 | 1 |
| Other (income) expense, net | (479) | (321) | (277) |
| Earnings before Taxes | 6,664 | 8,306 | 8,211 |
| Taxes on Earnings | 941 | 1,373 | 1,140 |
| Net Earnings | $5,723 | $6,933 | $7,071 |
| Basic Earnings Per Common Share | $3.28 | $3.94 | $3.97 |
| Diluted Earnings Per Common Share | $3.26 | $3.91 | $3.94 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share | 1,740 | 1,753 | 1,775 |
| Dilutive Common Stock Options | 9 | 11 | 14 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,749 | 1,764 | 1,789 |
| Outstanding Common Stock Options Having No Dilutive Effect | 5 | 3 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.